Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device in Brain-injured Patients

Overview

Clinical pilot study to evaluate a new multi-parameter neuromonitoring device that allows the measurement of regional cerebral blood flow (rCBF), intracranial pressure (ICP), brain temperature monitoring and ventricular cerebrospinal fluid (CSF) drainage in brain-injured patients.

Full Title of Study: “Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device That Allows the Measurement of Regional Cerebral Blood Flow (rCBF), Intracranial Pressure (ICP), Brain Temperature Monitoring and Ventricular Cerebrospinal Fluid (CSF) Drainage in Brain-injured Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Device Feasibility
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2024

Interventions

  • Device: Placement of the CBMS Probe
    • Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.

Arms, Groups and Cohorts

  • Experimental: CBMS

Clinical Trial Outcome Measures

Primary Measures

  • Feasibility: Comparability of regional CBF values and values obtained with CT perfusion and TCD
    • Time Frame: Up to 28 days until probe removal
    • Regional CBF values calculated with the investigational devices (CBMS) are within ranges described in literature, and dynamic changes of regional CBF are consistent to those values obtained with established methods CT perfusion and TCD.

Secondary Measures

  • Safety related to catheter insertion and monitoring
    • Time Frame: Until 7 days after probe removal
    • Safety related to catheter insertion and monitoring: local hematomas, infections, CSF drainage dysfunction in comparison with other standard intra-ventricular devices.

Participating in This Clinical Trial

Inclusion Criteria

  • Adult male or female patient, aged 18 – 75 years – Brain injured patients with acute intracranial hemorrhage (including aneurysmal subarachnoid hemorrhage (SAH) and spontaneous intracerebral hemorrhage (ICH)) who are admitted to the ICU and have an indication for ICP monitoring and CSF drainage, as per standard patient care – Informed consent obtained for research in emergency situations according to HRA art. 30 & 31 at time of inclusion Exclusion Criteria:

  • Known kidney disease, defined as plasma creatinine > 120 μmol/l – Known liver disease, defined as AST > 200 IU/L – Over-active thyroid or benign tumors of the thyroid – History of allergic disorders, including allergic reactions, against contrast agents containing iodine, or against ICG – Patients which have received one of the following medications before being admitted to ICU: Haloperidol, Meperidine, Methadone, Morphine, Phenobarbital and Rifamycin. – Patients with wounds or scars including the front orbital region. – Cerebrospinal fluid infection or signs of meningo-encephalitis – Anemia (hemoglobin < 10 g/dl) or Thalassemia – Carbon monoxide poisoning – Acquired pathological or congenital disorders of the cerebral system, being clinically significant, respectively interfering in the investigator's opinion with the conduct of study – Documented history of bleeding, clotting or coagulation disorders – Patients who are not suitable for a CT perfusion – Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical investigation or will not comply with requirements of the study – Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation – Pre-existing disability and/or legal representative – Patients who are kept lawfully in an institution – Participation in another interventional clinical investigation within the last 30 days before start of treatment – History of, respectively diagnosis of pregnancy, or breastfeeding patients

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Carag AG
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mauro Oddo, Prof. Dr., Principal Investigator, Centre Hospitalier Universitaire Vaudoise CHUV

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.